- 2020. Pentraxin 3 in primary percutaneous coronary intervention for ST elevation myocardial infarction is associated with early irreversible myocardial damage: Kinetic profile, relationship to interleukin 6 and infarct size. European Heart Journal: Acute Cardiovascular Care. 302-312.
- 2017. Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins. Cardiology. 122-132.
- 2014. Clinical use of optical coherence tomography to identify angiographic silent stent thrombosis. Scandinavian Cardiovascular Journal. 156-160.
- 2011. Response of growth differentiation factor-15 to percutaneous coronary intervention and regular exercise training. Scandinavian Cardiovascular Journal. 27-32.
- 2011. Endothelial dysfunction predicts clinical restenosis after percutaneous coronary intervention. Scandinavian Cardiovascular Journal. 139-145.
Reader opinion piece
- 2012. Symptoms of anxiety and depression after percutaneous coronary intervention are associated with decreased heart rate variability, impaired endothelial function and increased inflammation. International Journal of Cardiology. 173-176.
- 2014. Clinical use of optical coherence tomography to identify angiographic silent stent thrombosis (Scandinavian Cardiovascular Journal, 2014, 48 (156-160)). Scandinavian Cardiovascular Journal. 323-323.